Alliance Foundation Trial 09: A randomized, multicenter, phase 2 trial evaluating two sequences of pembrolizumab and standard platinum-based chemotherapy in patients with metastatic NSCLC
JTO Clinical and Research Reports
Open Access Publication
Rights and Permissions
Hensing TA, Wang X, Stinchcombe TE, Gao J, Knopp MV, Watson M, Dudek AZ, Graziano SL, Patel JD, Faller BA, Dragnev KH, Kozono D, Vokes EE. Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. JTO Clin Res Rep. 2021 Jul 13;2(8):100208. doi: 10.1016/j.jtocrr.2021.100208. Copyright 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/)
Hensing, Thomas A; Wang, Xiaofei; Stinchcombe, Thomas E; Gao, Junheng; Knopp, Michael V; Watson, Mark; Dudek, Arkadiusz Z; Graziano, Stephen L; Patel, Jyoti D; Faller, Bryan A; Dragnev, Konstantin H; Kozono, David; and Vokes, Everett E, "Alliance Foundation Trial 09: A randomized, multicenter, phase 2 trial evaluating two sequences of pembrolizumab and standard platinum-based chemotherapy in patients with metastatic NSCLC." JTO Clinical and Research Reports. 2, 8. 100208 (2021).
ICTS (Institute of Clinical and Translational Sciences)
Supplemental material is available for this article at publisher site.